IDiyas

For the Inventor, By the Inventor

The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Patent No.:

US 11981618 B1

PDFFull Text
Date of Patent:
May. 14, 2024

Filed:

Jul. 24, 2019

P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same

Applicant:

Autotac Inc., Seoul, KR;

Inventors:

Yong Tae Kwon, Seoul, KR;

Chang Hoon Ji, Seoul, KR;

Srinivasrao Ganipisetti, Seoul, KR;

Hee Yeon Kim, Seoul, KR;

Su Ran Mun, Seoul, KR;

Chan Hoon Jung, Seoul, KR;

Eui Jung Jung, Seoul, KR;

Ki Woon Sung, Seoul, KR;

Assignee:

AUTOTAC INC., Seoul, KR;

Attorney:

Sughrue Mion, PLLC

Primary Examiner:

Taylor V Oh

Int. Cl.
CPC ...
C07C 217/58 (2006.01); A23L 33/10 (2016.01); A61K 31/05 (2006.01); A61K 31/12 (2006.01); A61K 31/138 (2006.01); A61K 31/166 (2006.01); A61K 31/192 (2006.01); A61K 31/277 (2006.01); A61K 31/336 (2006.01); A61K 31/355 (2006.01); A61K 31/4015 (2006.01); A61K 31/4155 (2006.01); A61K 31/4184 (2006.01); A61K 31/421 (2006.01); A61K 31/428 (2006.01); A61K 31/4535 (2006.01); A61K 31/4709 (2006.01); A61K 31/4745 (2006.01); A61K 31/496 (2006.01); A61K 31/50 (2006.01); A61K 31/5025 (2006.01); A61K 31/506 (2006.01); A61K 31/517 (2006.01); A61K 31/5377 (2006.01); A61K 31/5415 (2006.01); A61K 31/551 (2006.01); A61K 31/565 (2006.01); A61K 39/395 (2006.01); A61K 47/54 (2017.01); A61K 47/55 (2017.01); A61K 47/68 (2017.01); A61P 25/28 (2006.01); C07C 43/23 (2006.01); C07C 47/575 (2006.01); C07C 235/06 (2006.01); C07C 237/06 (2006.01); C07C 275/24 (2006.01); C07C 279/12 (2006.01); C07D 303/18 (2006.01);
U.S. Cl.
CPC ...
C07C 217/58 (2013.01); A23L 33/10 (2016.08); A61K 31/05 (2013.01); A61K 31/12 (2013.01); A61K 31/138 (2013.01); A61K 31/166 (2013.01); A61K 31/192 (2013.01); A61K 31/277 (2013.01); A61K 31/336 (2013.01); A61K 31/355 (2013.01); A61K 31/4015 (2013.01); A61K 31/4155 (2013.01); A61K 31/4184 (2013.01); A61K 31/421 (2013.01); A61K 31/428 (2013.01); A61K 31/4535 (2013.01); A61K 31/4709 (2013.01); A61K 31/4745 (2013.01); A61K 31/496 (2013.01); A61K 31/50 (2013.01); A61K 31/5025 (2013.01); A61K 31/506 (2013.01); A61K 31/517 (2013.01); A61K 31/5377 (2013.01); A61K 31/5415 (2013.01); A61K 31/551 (2013.01); A61K 31/565 (2013.01); A61K 39/3955 (2013.01); A61K 47/54 (2017.08); A61K 47/55 (2017.08); A61K 47/6803 (2017.08); A61K 47/6849 (2017.08); A61P 25/28 (2018.01); C07C 43/23 (2013.01); C07C 47/575 (2013.01); C07C 235/06 (2013.01); C07C 237/06 (2013.01); C07C 275/24 (2013.01); C07C 279/12 (2013.01); C07D 303/18 (2013.01); C07B 2200/07 (2013.01);
Abstract

The present invention relates to a novel p62 ligand compound, a stereoisomer, hydrate, solvate or prodrug thereof, and a pharmaceutical or food composition for preventing or treating proteinopathies comprising the same as an active ingredient. The p62 ligand compound according to the present invention can be usefully used as a pharmaceutical composition for the prevention, amelioration or treatment of various proteinopathies by activating autophagy in cells and thus selectively eliminating in vivo proteins, organelles and aggregates.

Find Patent Forward Citations

Loading…